Literature DB >> 7424173

[Drug safety: activities of the manufacturer].

P Krupp.   

Abstract

Many activities of the pharmaceutical manufacturers concern drug safety to that any comprehensive description appears rather difficult. Special attention has however been given to the following four areas: The Research Department is engaged in developing novel and still safer medicines, while the Drug Monitoring unit specializes in early recognition of yet unknown and possibly harmful effects of already marketed drugs; the Product Information orientates on the risk and benefit, and finally the Quality Control ensures that the consumer is provided with high-quality products. However, despite all these measures an absolute drug safety cannot be achieved since a given risk is inherent in every drug therapy.

Mesh:

Year:  1980        PMID: 7424173     DOI: 10.1007/bf02075063

Source DB:  PubMed          Journal:  Soz Praventivmed        ISSN: 0303-8408


  5 in total

1.  Post-marketing surveillance of adverse reactions to new medicines.

Authors:  A B Wilson
Journal:  Br Med J       Date:  1977-10-15

Review 2.  Postmarketing surveillance of new drugs: I. Review of objectives and methodology.

Authors:  W M Wardell; M C Tsianco; S N Anavekar; H T Davis
Journal:  J Clin Pharmacol       Date:  1979 Feb-Mar       Impact factor: 3.126

Review 3.  Recognition of unwanted drug effects.

Authors:  R Doll
Journal:  Br Med J       Date:  1969-04-12

4.  Comprehensive drug surveillance.

Authors:  H Jick; O S Miettinen; S Shapiro; G P Lewis; V Siskind; D Slone
Journal:  JAMA       Date:  1970-08-31       Impact factor: 56.272

5.  Clinically significant adverse effects in a Phase 1 testing program.

Authors:  C J Zarafonetis; P A Riley; P W Willis; L H Power; J Werbelow; L Farhat; W Beckwith; B H Marks
Journal:  Clin Pharmacol Ther       Date:  1978-08       Impact factor: 6.875

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.